City of Hope recently announced the appointment of John D. Carpten, PhD, as Director of the National Cancer Institute (NCI)-designated comprehensive cancer center, Director of Beckman Research Institute of City of Hope, and Chief Scientific Officer. Dr. Carpten will also hold the Irell &...
Emergency department (ED) visits by patients with cancer increased by 67.1% between the start of 2012 and the end of 2019, compared with an increase of just 7.5% in cancer incidence, according to a recent study in JAMA Network Open.1 Factors identified as possible explanations for the...
The American Association for Cancer Research (AACR) presented Olivier Delattre, MD, PhD, with the 2023 AACR–St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research during the AACR Annual Meeting 2023 in April in Orlando, Florida. Dr. Delattre is Director of the...
Screening that reduces cancer mortality serves as a foundational element of impactful care for certain cancers. That said, harms related to screening deserve our attention—overdiagnoses; diagnostic odysseys that may be invasive, expensive, or even unintentionally harmful; overtreatment of diagnosed ...
Researchers have found that studying the landscape of DNA and RNA alterations across multiple organs of metastasis may provide a new direction in cancer therapeutics to address treatment failure, according to a new study published by Liu et al in Nature Medicine. The new findings from analyzing...
Researchers may have discovered a new therapeutic target for patients with breast cancer—the TONSL gene—while attempting to understand the mechanisms behind breast cancer cell pathogenesis, according to a novel study published by Khatpe et al in Cancer Research. “Most of the cancer research to date ...
This is Part 2 of Advances in Follicular Lymphoma, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Stephen M. Ansell, Loretta J. Nastoupil, and Gilles Salles discuss the management of recurrent follicular lymphoma. The patient...
Bone marrow transplantation in leukemia is one of the great success stories in the history of oncology, as is that of the late Nobel Laureate E. Donnall Thomas, MD, the pioneering clinical researcher whose name is synonymous with life-saving marrow transplantation. Dr. Thomas, who was born in the...
Investigators have found that vitamin D deficiencies may contribute to more aggressive prostate cancer in Black patients at a younger age compared with White patients, according to a new study published by Siddappa et al in Cancer Research Communications. The new findings could pave the way for...
Chemotherapy may be associated with a 71% increased risk of treatment-related cardiotoxicity—including heart failure and cerebrovascular disease—among Black patients or patients of African ancestry compared with White patients, according to new findings presented by Gebeyehu et al at the American...
This is Part 3 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of locally advanced high-risk...
This is Part 2 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss the management of de novo metastatic...
This is Part 1 of Novel Hormonal Therapies for Prostate Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Alicia K. Morgans, Neeraj Agarwal, and David VanderWeele discuss biochemical recurrence in prostate cancer. The...
Researchers have created the largest single-cell atlas of renal cell carcinoma brain metastases, with matched primary and extracranial metastases, which has potentially enabled them to discover key biological mechanisms contributing to an immunosuppressive tumor microenvironment in the brain...
Researchers revealed that 39.2% of patients who consented to whole-exome sequencing and were identified as carriers of predisposition genes for hereditary breast and ovarian cancer or Lynch syndrome did not qualify for genetic screening under current guidelines, according to new findings presented...
Guest Editor’s Note: Despite its high prevalence, cancer pain remains undertreated. Racial disparities present further challenges to assessing and managing pain. Music therapy, a nonpharmacologic intervention, has been documented to be effective in controlling cancer pain. In this article, Kevin T. ...
The U.S. Preventive Services Task Force (USPSTF) recently announced the appointments of Michael J. Barry, MD, as Chair, and Michael Silverstein, MD, MPH, as Vice Chair. Wanda K. Nicholson, MD, MPH, MBA, will remain in her role as Vice Chair. Dr. Barry will assume the role of Chair from Carol M....
On March 9, 2023, President Joseph Biden released his proposed Fiscal Year (FY) 2024 federal budget, with an emphasis on increased funding for medical research and expanded access to health insurance. The proposal allocates $48.3 billion for the National Institutes of Health (NIH), an $811 million ...
The Lymphoma Research Foundation (LRF) has announced the creation of the Kanti R. Rai, MD, Clinical Scholar Program to fund the ongoing study of lymphoma and chronic lymphocytic leukemia (CLL). Established in recognition of the global leadership of Kanti R. Rai, MD, in the field of lymphoma and CLL ...
Researchers have demonstrated that patients with low-grade lymphomatoid granulomatosis who were treated with the immunotherapy interferon alfa-2b may survive for a median of 20 years after diagnosis, according to a novel study published by Melani et al in The Lancet Haematology. The findings...
“Providing hope when there is little to hope for is hard,” noted Hyman B. Muss, MD, Professor of Medicine and the Mary Jones Hudson Distinguished Professor of Geriatric Oncology at the University of North Carolina at Chapel Hill and the Lineberger Comprehensive Cancer Center. At the 2023 Miami...
Investigators have revealed the findings from an examination of the prevalence, severity, and co-occurrence of sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy/fatigue (SPPADE) symptoms, as well as their association with different cancer types and patient...
Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
Formal discussant of the FORMULA-509 trial, Tyler Seibert, MD, PhD, of the University of California San Diego, commented: “The important take-away of these results is who benefited from the intensification arm. The overall cohort with a PSA [prostate-specific antigen] level up to 0.5 ng/mL did not, ...
The addition of abiraterone acetate and apalutamide to standard of care gonadotropin-releasing hormone (GnRH) agonist for 6 months and radiation therapy failed to improve progression-free survival and metastasis-free survival after prostatectomy compared to bicalutamide plus a GnRH agonist and...
The American Associationfor Cancer Research (AACR) will award Carl H. June, MD, FAACR, Fellow of the AACR Academy, with the 2023 AACR Award for Lifetime Achievement in Cancer Research during the 2023 AACR Annual Meeting, April 14–19 in Orlando, Florida. Dr. June is the Richard W. Vague Professor in ...
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Northwell Health has appointed Richard D. Carvajal, MD, a clinician and researcher in melanoma and early-phase drug development, as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute. He also was named the R. J. Zuckerberg Chair in Medical Oncology....
Three researchers at The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS) for their notable contributions to the field of cancer research. This distinction is one of the highest honors in the scientific research...
The University of Arkansas for Medical Sciences (UAMS) recently announced the appointment of Rangaswamy Govindarajan, MD, as Chief of the Division of Hematology and Oncology at the UAMS Winthrop P. Rockefeller Cancer Institute. Dr. Govindarajan, who is also Professor in the division, will lead a...
“There is and always has been, more to me than medicine. Ever since the university, I have loved flying. Ever since school, I have adored choral singing,” writes John F. Smyth, MD, in his memoir Taming the Beast: Memoirs of a Pioneering Cancer Physician. Dr. Smyth is Emeritus Professor of Medical...
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Vivek Subbiah, MD, Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine Division, at The University of Texas MD Anderson Cancer Center, ...
Researchers have found that postoperative physical activity was associated with improved disease-free survival among patients previously treated for stage III colorectal cancer, according to a novel study published by Brown et al in the British Journal of Sports Medicine. “With March being National ...
This is Part 3 of The Evolving Targeted Treatment Landscape for Colorectal Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. John Strickler, Stacey A. Cohen, and Harshabad Singh discuss the first-line treatment of...
Use of the novel menin inhibitor revumenib has led to remissions in patients with acute myeloid leukemia (AML), and associated findings have suggested the mechanisms through which cancer cells may become resistant to such treatment, according to two studies published by Issa et al and Perner et al, ...
The American Society for Transplantation and Cellular Therapy (ASTCT) has chosen Miguel-Angel Perales, MD, as President of the Society in 2023–2024. Dr. Perales first served on the Board of Directors in 2017 and has been a member of ASTCT since 2001. He is Chief of the Adult Bone Marrow...
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UMPC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, Professor of Radiology at UMPC Magee-Womens Hospital, all of the University of Pittsburgh School of Medicine, have received ...
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
Sumanta K. Pal, MD, introduces his City of Hope colleagues, Hedyeh Ebrahimi, MD, MPH, who discusses the prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma, and Daniela Castro, MSc, who discusses expanding eligibility criteria in kidney, prostate,...
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
On February 2, 2023, President Joseph Biden announced his intent to appoint six members to the National Cancer Advisory Board (NCAB). The NCAB plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. The NCAB...
Although there is no history of cancer in my family, I guess it isn’t surprising that I would develop an aggressive form of melanoma on my scalp after years of ultraviolet radiation from sun exposure. Still, getting the diagnosis was devastating. I first noticed a small lump on the top of my head ...
The widespread use of immune checkpoint inhibitors has led to significant benefits in younger patients with advanced lung cancer; however, older patients have not experienced similar survival benefits, according to research from Yale Cancer Center. The study was published in JAMA Oncology.1 “There ...
This is Part 4 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss the second- and third-line therapy options for unresectable and metastatic melanoma. The...
This is Part 2 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss current adjuvant treatment options in malignant melanoma. The patient is a 67-year-old man ...
This is Part 1 of Updates in Melanoma, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Omid Hamid, Sapna Patel, and Ryan Sullivan discuss current adjuvant treatment options in malignant melanoma. The patient is a 67-year-old man ...